Sarepta Therapeutics 4.95M share Spot Secondary priced at $25.25 The deal priced at the high end of the $25.00-$25.25 range and was increased to $125M in common stock. Lazard Capital acted as sole book running manager for the offering.
News For SRPT From The Last 14 Days
Check below for free stories on SRPT the last two weeks.
Nebraska Medical Center not naming Ebola drug, The Street reports Nebraska Medical Center is not releasing the name of the experimental Ebola drug being given to Dr. Rick Sacra, The Street's Adam Feuerstein reports, citing an emailed response from the hospital. Traders are speculating Tekmira (TKMR) is the manufacturer of the drug, Feuerstein points out. Sarepta (SRPT) disclosed that it is not involved in the treatment of Sacra, added Feuerstein. Shares of Tekmira are up 3% to $19.65 in morning trading. Reference Link